146 related articles for article (PubMed ID: 37883738)
1. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.
Verheij FS; Omer DM; Williams H; Lin ST; Qin LX; Buckley JT; Thompson HM; Yuval JB; Kim JK; Dunne RF; Marcet J; Cataldo P; Polite B; Herzig DO; Liska D; Oommen S; Friel CM; Ternent C; Coveler AL; Hunt S; Gregory A; Varma MG; Bello BL; Carmichael JC; Krauss J; Gleisner A; Guillem JG; Temple L; Goodman KA; Segal NH; Cercek A; Yaeger R; Nash GM; Widmar M; Wei IH; Pappou EP; Weiser MR; Paty PB; Smith JJ; Wu AJ; Gollub MJ; Saltz LB; Garcia-Aguilar J
J Clin Oncol; 2024 Feb; 42(5):500-506. PubMed ID: 37883738
[No Abstract] [Full Text] [Related]
2. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
Garcia-Aguilar J; Patil S; Gollub MJ; Kim JK; Yuval JB; Thompson HM; Verheij FS; Omer DM; Lee M; Dunne RF; Marcet J; Cataldo P; Polite B; Herzig DO; Liska D; Oommen S; Friel CM; Ternent C; Coveler AL; Hunt S; Gregory A; Varma MG; Bello BL; Carmichael JC; Krauss J; Gleisner A; Paty PB; Weiser MR; Nash GM; Pappou E; Guillem JG; Temple L; Wei IH; Widmar M; Lin S; Segal NH; Cercek A; Yaeger R; Smith JJ; Goodman KA; Wu AJ; Saltz LB
J Clin Oncol; 2022 Aug; 40(23):2546-2556. PubMed ID: 35483010
[TBL] [Abstract][Full Text] [Related]
3. Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA Trial.
Verheij FS; Omer DM; Lin ST; Yuval JB; Thompson HM; Kim JK; Valdivieso SC; Qin LX; Wu AJ; Saltz LB; Garcia-Aguilar J
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):115-123. PubMed ID: 37544412
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series.
Asoglu O; Bulut A; Aliyev V; Piozzi GN; Guven K; Bakır B; Goksel S
World J Surg Oncol; 2022 Nov; 20(1):358. PubMed ID: 36352416
[TBL] [Abstract][Full Text] [Related]
5. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
6. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
7. Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy.
Jimenez-Rodriguez RM; Quezada-Diaz F; Hameed I; Kalabin A; Patil S; Smith JJ; Garcia-Aguilar J
Dis Colon Rectum; 2021 Dec; 64(12):1463-1470. PubMed ID: 34508014
[TBL] [Abstract][Full Text] [Related]
8. Salvage Surgery With Organ Preservation for Patients With Local Regrowth After Watch and Wait: Is It Still Possible?
Fernandez LM; Figueiredo NL; Habr-Gama A; São Julião GP; Vieira P; Vailati BB; Nasir I; Parés O; Santiago I; Castillo-Martin M; Carvalho C; Parvaiz A; Perez RO
Dis Colon Rectum; 2020 Aug; 63(8):1053-1062. PubMed ID: 32692070
[TBL] [Abstract][Full Text] [Related]
9. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.
Thompson HM; Omer DM; Lin S; Kim JK; Yuval JB; Verheij FS; Qin LX; Gollub MJ; Wu AJ; Lee M; Patil S; Hezel AF; Marcet JE; Cataldo PA; Polite BN; Herzig DO; Liska D; Oommen S; Friel CM; Ternent CA; Coveler AL; Hunt SR; Garcia-Aguilar J;
JAMA Netw Open; 2024 Jan; 7(1):e2350903. PubMed ID: 38194231
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
Fokas E; Schlenska-Lange A; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Kirste S; Jacobasch L; Allgäuer M; Flentje M; Germer CT; Grützmann R; Hildebrandt G; Schwarzbach M; Bechstein WO; Sülberg H; Friede T; Gaedcke J; Ghadimi M; Hofheinz RD; Rödel C;
JAMA Oncol; 2022 Jan; 8(1):e215445. PubMed ID: 34792531
[TBL] [Abstract][Full Text] [Related]
11. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
12. Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Cotti GC; Pandini RV; Braghiroli OFM; Nahas CSR; Bustamante-Lopez LA; Marques CFS; Imperiale AR; Ribeiro U; Salvajoli B; Hoff PM; Nahas SC
Dis Colon Rectum; 2022 Mar; 65(3):333-339. PubMed ID: 34775415
[TBL] [Abstract][Full Text] [Related]
13. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).
Serra-Aracil X; Pericay C; Badia-Closa J; Golda T; Biondo S; Hernández P; Targarona E; Borda-Arrizabalaga N; Reina A; Delgado S; Vallribera F; Caro A; Gallego-Plazas J; Pascual M; Álvarez-Laso C; Guadalajara-Labajo HG; Mora-Lopez L
Ann Oncol; 2023 Jan; 34(1):78-90. PubMed ID: 36220461
[TBL] [Abstract][Full Text] [Related]
14. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
[TBL] [Abstract][Full Text] [Related]
15. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
[TBL] [Abstract][Full Text] [Related]
16. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
[TBL] [Abstract][Full Text] [Related]
17. Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial.
Fan WH; Wang FL; Lu ZH; Pan ZZ; Li LR; Gao YH; Chen G; Wu XJ; Ding PR; Zeng ZF; Wan DS
Chin J Cancer; 2015 Jun; 34(9):394-403. PubMed ID: 26111932
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
19. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
20. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
